GETTESTED
LIVE

Serial Number

79420693

Owner

Get Tested International AB

Attorney

John Alumit

Filing Date

Dec 16, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GETTESTED Trademark

Serial Number: 79420693

GETTESTED is a trademark filed by Get Tested International AB on December 16, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Get Tested International AB

Mörtnäs hagväg 3

Entity Type: 98

Trademark Details

Filing Date

December 16, 2024

Registration Date

Not Registered

Published for Opposition

May 12, 2026

Goods & Services

diagnostic preparations and materials, for medical and veterinary purposes, namely, Medical diagnostic assays for testing body fluids and saliva ; medical and veterinary preparations relating to home tests, namely, Genetic identity tests comprised of reagents for medical purposes, Medical diagnostic reagents and assays for testing body fluids for microorganisms; medical diagnostic test strips for use in the field of gut health, thyroid health, heart health, metabolism, fertility, hormones, vitamin deficiency, allergies, male and female testosterone, insulin, menopause, adrenal function, ovarian reserves, hormones, ovarian function, menstrual irregularities, menopause; medical reagents for use in diagnostic tests; diagnostic reagents for medical use; chemical test reagents for medical use; medical diagnostic reagents and assays for testing of body fluids; diagnostic strips for testing, for medical purposes for gut health, thyroid health, heart health, metabolism, fertility, hormones, vitamin deficiency, allergies, male and female testosterone, insulin, menopause, adrenal function, ovarian reserves, hormones, ovarian function, menstrual irregularities, menopause; in vitro diagnostic preparations for medical use; in vitro test kits, for medical use, namely, in-vitro ovulation prediction test kit for home use; in vitro test kits, for medical use, all the aforesaid goods adapted for home use, namely, in-vitro ovulation prediction test kit for home use;; chemical preparations for use in dna analysis for medical purposes; genetic identity tests comprised of reagents for medical purposes; preparations for detecting genetic predispositions for medical purposes; medical reagents for use in analysis; medical diagnostic test kits comprised of medical diagnostic reagents and assays for testing body fluids; medical diagnostic test kits, for household use comprised of medical diagnostic reagents and assays for testing body fluids; medical test kits, namely, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, infections, sexually transmitted diseases, chlamydia, gonorrhea, syphilis, herpes, Hepatitis B and C, diabetes, liver and kidney disease, cancer, trichomonas and mycoplasma, cardiovascular disease, tumors, and hormone imbalances, high cholesterol, hormone imbalance, vitamin deficiencies, stroke, cognitive decline, infertility, ovarian problems, menstrual irregularities

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 12, 2026 NPUB
PUBLISHED FOR OPPOSITION
May 12, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 6, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 16, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 1, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 1, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 1, 2026 TROA
REFUSAL PROCESSED BY IB
Mar 26, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 10, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 10, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 7, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 6, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 24, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 23, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 23, 2026 NWOS
NEW REPRESENTATIVE AT IB RECEIVED
Jul 11, 2025 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jun 20, 2025 NREP
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 3, 2025 REPR